

LEGAL DISCLAIMER

NOTICE TO RECIPIENT

This investment is suitable only for sophisticated investors for whom an investment does not constitute a complete investment program, who do not require immediate liquidity for their investment and who fully understand and are willing to assume the risks involved. An investment may be considered to involve a substantial degree of risk, and an investor could lose all or a substantial amount of his or her investment. This document is not an offer to sell (or solicitation of an offer to buy) any interest in the Company. These materials may not be used or relied upon for any purpose other than as specifically contemplated by a written agreement. The materials may not be circulated outside of the recipient's organization, publicly referred to, or disclosed, in whole or in part, without express written permission. This presentation does not purport to be all inclusive or contain all the information that a prospective investor may require to fully evaluate an investment in the contemplated transaction. Prospective investors should conduct their own thorough investigation and due diligence before making an investment.

DISCLAIMER

This Presentation contains forward-looking statements and forward-looking information. Often, but not always, forward-looking statements can be identified by the use of words or phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and risks, uncertainties and other factors, which may cause the actual results. performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and information. Examples of such statements include: (A) the financial forecast of the Company: (B) the intention to grow the business and operations of the Company; (C) anticipated timing for the availability of the Company's products to market and expected sale prices; (D) expected growth in the number of users of medical and recreational marijuana anticipated in North America, United Kingdom and Europe; and (E) the expansion of the Company's business into other revenue streams. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this Presentation. Such forward-looking statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to: the ability of the Company to obtain necessary financing; the ability to complete a going public transaction; the ability to satisfy the requirements of a stock exchange; the economy generally; consumer interest in the products of the Company; competition; and anticipated and unanticipated costs. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this Presentation. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements and information contained in this Presentation are expressly qualified in their entirety by this cautionary statement. The forward-looking statements and information included in this Presentation are made as of the date of this Presentation and the Company assumes no obligation to update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Executive Summary

Invictus MD is focused on two verticals:

- 1. Cannabis cultivation in Canada under the ACMPR
- 2. Cannabis fertilizer and nutrients



REALIZED RETURN ON INVESTMENT

Invictus MD went public December 2014.

To date the company acquired and sold the following assets:

INVESTEE	% OWNERSHIP	COST TO ACQUIRE	PROCEEDS ON DISPOSAL	GAIN (LOSS) ON DISPOSAL	RETURN ON INVESTMENT	HOLDING PERIOD
Future Harvest - Sunblaster	75%	\$900,000	\$3,750,000	\$2,850,000	316%	11 months
Smokazon	35%	\$155,000	\$123,000	(\$32,000)	(21%)	10 months
Cannabis Health	100%	\$45,000	\$275,000	\$230,000	511%	10 months
		\$1,100,000	\$4,148,000	\$3,048,000	277%	

Invictus MD paid out a \$1,000,000 dividend to shareholders on December 5, 2016 Representing \$0.07 per share.

BOARD OF DIRECTORS

DAN KRIZNIC cpa/ca, executive chairman, ceo, founder & director

Dan Kriznic founded Invictus MD in June 2014 with a vision to create Canada's Cannabis Company to meet the significant legal demand. He has been responsible for incubating companies in a variety of industry including Cannabis, Education, Real Estate, Resources and Senior Care Facilities. Through his strategic direction and execution, these companies have grown from nominal amount to a Billion in enterprise value. Prior to this, he was a Senior Manager at Deloitte where he served in leadership roles in its Assurance and Advisory group, advising public and privately held companies for a period of 10 years.

TREVOR DIXON DIRECTOR

Trevor Dixon founded Acreage Pharms Ltd in 2013 and with his sister Brenda Dixon, Chief Science Officer, submitted a successful ACMPR application. Prior to that, founded a company that specialized in niche home renovations where he developed a franchise system. Within a decade the company was serving customers in more than 50 cities across Canada. His philosophy of customer value, quality, and excellent service has been carried over into the design and operational strategy of Acreage Pharms Ltd. and Invictus MD.

GEORGE KVETON DIRECTOR

George is a founding partner of LOGSCALE Venture Partners; focused on capitalizing early and growth stage companies in healthcare. He has in-depth strategic and corporate development experience in fast moving consumer goods. As VP at Japan Tobacco he led M&A transactions valued at US \$1.5B, expansion into in the US and Latin America, and deal origination and execution for emerging products. At Philip Morris he led two major acquisitions (up to U\$1B), readied businesses in Central and Eastern European for EU accession, and facilitated new market entries into Croatia and neighboring countries. His multi-billion dollar private and public company deals are global spanning five continents. He's a grad of Queen's University and completed executive studies at Berkeley Haas and Harvard Business School.

BOARD OF DIRECTORS

AARON BOWDEN CPA/CA, DIRECTOR

Aaron Bowden specializes in taxation and currently manages all areas of taxation for a large Canadian public company with over 12,000 employees and \$4 billion in sales. Prior to this Mr. Bowden worked at Deloitte advising clients on assurance and tax matters and has been involved in various forms of financing, mergers, acquisitions, and divestitures.

JOSEF HOCHER DIRECTOR

Mr. Josef W. Hocher was a founder of Buried Hill Energy, an international oil and gas company, where he acted as co-chief executive in creating, developing and implementing the organization's strategic direction. He continues to serve as the Senior Independent Director and is also either a Chair or a member of various committees. Joe also founded Hitic Energy Ltd., and was a partner at Osler, Hoskin & Harcourt LLP. Joe currently serves as Chairman of Orthoshop Geomatics Ltd., a geomatics services company; holds the position of Chief Commercial Officer at Field Upgrading Limited and Western Hydrogen Limited and since 2016, has been a Partner at Cassels, Brock & Blackwell LLP.

PAUL SPARKES DIRECTOR

Paul Sparkes sits on several public and private boards in Canada, the US and Europe, including Thunderbird Entertainment, Bluedrop Performance Learning, Inc., and is a former board member of the Liquor Control Board of Ontario (LCBO). Prior to joining Bell Globemedia in 2001 as Group Vice-President, Public Affairs, Mr. Sparkes held senior positions in public service, with the Governments of Canada, and Newfoundland and Labrador. As Executive Vice Chair, Director and co-founder of Difference Capital Financial, a TSX-listed specialty finance company that invested in media, technology, health care and US real estate, he helped raise over \$200 million for investment purposes in under a year.

MANAGEMENT

HERRICK LAU CFA, CHIEF FINANCIAL OFFICER

Mr. Lau, currently the Managing Director of Baron Global Financial Canada Ltd., has over 20 years of experience in financial management and corporate finance. As a senior financial executive, he has acted as CFO and, or a director for various public companies listed on the TSX, TSXV and CSE. Mr. Lau holds Bachelor and Master's degrees in Business and Economics from Simon Fraser University and is a charter holder of the Chartered Financial Analyst (CFA) designation.

LARRY HEINZLMEIR MBA VICE PRESIDENT, MARKETING & COMMUNICATIONS

Larry Heinzlmeir brings over twenty-five years of executive level experience in sales and marketing with several of the largest publicly traded companies in the for-profit higher education sector, namely DeVry and EDMC, that had a combined market cap in excess of \$7B. He was Vice President, Marketing and CMO of a growth-oriented organization that was Canada's largest private, for profit, education company and was responsible for the aggressive growth of seven brands growing revenue ten-fold in four years. He has extensive experience in developing marketing strategies, multi-brand development, product management, communications, creative and content development, and leveraging digital marketing across multiple platforms and technologies including web, mobile and social.

ACMPR Share Price Performance has Accelerated since the task force discussion paper was released in June 2016



Potential timing of a recreational roll-out


 $2016 \rightarrow 2017 \rightarrow 2018 \rightarrow 2019-20 \rightarrow 2021+$

November
Task Force Update

April Legislation Tabled Mid-Year Recreational Rollout Ramp-up Recreatational Sales Recreational Market Reaches Normalised State

According to Deloitte Canadian recreational cannabis could reach retail sales of \$6.0 billion by 2021


Supply, demand and pricing:total market



Source: Health Canada; Public Company LP Reports; Canaccord Genuity estimates

CANACCORD Genuity

INVICTUS MD's CANADIAN CANNABIS PLATFORM




Production | Acreage Pharms Ltd.

West-Central, Alberta

Phase 1 - Exisiting

- 6,800 sq ft purpose built concrete and steel facility
- 500 kg cannabis cultivation capacity per annum
- Level 8 vault allows for storage onsite of \$31.125MM of dried cannabis
- The current 150-acre property can accommodate future expansion plans
- Invictus MD owns 100% of Acreage Pharms






Production | Acreage Pharms Ltd.

West-Central, Alberta

Phase 2 - Funded Expansion

- 27,000 sq ft purpose built concrete and steel facility
- 3,350 kg cannabis cultivation capacity per annum
- Purpose built concrete and steel facility
- · Level 8 vault will allow for storage onsite of \$31.125MM of product
- \$6.0MM Project (in process of securing development permit, expected to complete construction by end of 2017)

FULLY FUNDED




Production | Acreage Pharms Ltd.

West-Central, Alberta

Phase 3 - Expansion

- 76,750 sq ft purpose built concrete and steel facility
- 9,210 kg cannabis cultivation capacity per annum
- \$16.5MM Project expected to be completed by June 2018 - subject to permitting

FULLY FUNDED






Production | AB Laboratories Inc.

Hamilton, Ontario

- •16,000 sq ft purpose built concrete and steel facility
- •1,000 kg cannabis cultivation capacity per annum
- Actively seeking adjoining properties for direct expansion to the existing facility
- •Invictus MD owns 33 1/3 of AB Laboratories Inc.





Production AB Ventures Inc.

Hamilton, Ontario

Phase 1: Funded Expansion:

- •21,000 sq ft expansion plan is expected to be completed by the end of 2017 with an additional 21,000 sq ft building envelope
- •3,000 kg cannabis cultivation capacity per annum
- Purpose built concrete and steel facility
- •\$5.5 MM projected cost for Phase 1 expansion
- Fully funded subject to permitting





Capacity

Funded Invictus MD Combined

	Cash	Construction Price per Sq. Ft	Sq. Ft.	Estimated kgs	Ownership	Net kgs to Invictus MD
Cash balance June 7, 2017	\$30MM					
General and administrative	(\$2MM)					
Acreage Pharms						
Existing			6,800	500	100%	500
Phase 2	(\$6MM)	\$215	27,000	3,350	100%	3,350
Phase 3	(\$16.5MM)	\$215	76,750	9,000	100%	9,000
AB Labs						
Existing			16,000	1,000	33.3%	640
AB Ventures						
Phase 1	(\$5.5MM)	\$215	21,000	3,000	33.3%	1,023
Total	0		147,550	16,850		14,513

Production Profile Forecast

Year	Acreage Pharms (kgs)	AB Labs (kgs)	AB Ventures (kgs)	Total (kgs)
2017	50	250	Ο	400
2018	3,850	1,000	3,000	7,850
2019	8,000	1,000	8,000	17,000
2020	15,000	1,000	15,000	31,000
2021	25,000	1,000	24,000	50,000


Funded capacity at 16,850 kgs.

Estimated additional capital to achieve full 50,000 kg production profile by 2021 = \$47.5MM

Capital injection from warrants estimated at \$44MM

FUTURE HARVEST(82.5% owned)

A premier manufacturer and distributor in the hydroponic and indoor growing industry for over 20 years, 95% of what we sell is our own innovative design 40+ proprietary products.



^{*}all figures exclude Sunblaster

Road Map

December	2014	Invictus MD goes public on CSE
March	2015	Invictus MD acquired 20% minority stake in Future Harvest Development (FHD) (fertilizer and lighting)
July	2015	Invictus MD acquired majority stake in FHD
February	2016	Invictus MD sold off Sunblaster Lighting for \$5 million (Division of FHD)
December	2016	Invictus MD pays \$1 million dividend to shareholders representing \$0.07 per share
December	2016	Invictus MD raises \$12 million and closes 33 1/3% of AB Laboratories (Licensed Producer under ACMPR)
March	2017	Closed \$16.21 million bought deal
March	2017	AB Labs commences cultivation
March	2017	Listed on TSX-V
March	2017	Acreage Pharms receives license under ACMPR
April	2017	Invictus MD completes acquisition of Acreage Pharms Ltd.
May	2017	Closed \$25 million bought deal
May	2017	AB Ventures closed 100 acre land acquisition. Once licensed under ACMPR will be used for future cannabis cultivation
December	2017	Estimated cultivation license for AB Ventures. Production profile for AB Labs & AB Ventures forecasted to reach 25,000 kgs by 2020
December	2020	Acreage Pharms production profile forecasted to reach 25,000 kgs by 2021

Capitalization Structure

Total Outstanding: 77,587,881

Outstanding options: 5,415,000

Outstanding Warrants: 27,246,347

Total shares fully diluted: 110,249,228



TSXV:IMH
OTC:IVITF
FRANKFURT: 81S

77.6MMBasic shares outstanding

\$30MM Cash

Invictus MD

Contact

Larry A Heinzlmeir

Vice President, Marketing & Communications larry.heinzlmeir@invictus-md.com 604.537.8676

